Previous Page  92 / 94 Next Page
Information
Show Menu
Previous Page 92 / 94 Next Page
Page Background

90

NCCN Guidelines for Patients

®

:

Rectal Cancer, Version 1.2017

Index

Index

2

nd

opinion

78

ablation

39, 58, 63–64

biologic therapy

see targeted therapy

BRAF mutation

21–22

cancer staging

13, 16, 46

carcinoembryonic antigen (CEA)

18, 50–51, 60–62

carcinoma in situ

13

chemotherapy

31–37, 39, 41, 44–46, 48, 50 , 52–53,

56–60, 63–71

clinical trial

39–41, 48, 58, 67–70, 75

colonoscopy

16–17, 47, 50–51, 61–62

complementary and alternative medicine (CAM)

40

complete blood count (CBC)

18

computed tomography (CT)

16, 18–19, 28–29,

44–51, 58, 62–64

digestive tract

8–9

familial adenomatous polyposis (FAP)

15

hereditary non-polyposis rectal cancer (HNPCC)

15

Lynch syndrome

15, 21–22

medical history

15–16, 22, 50–51, 60–61

metastasectomy

26, 57–58, 63–64

microsatellite instability (MSI)

16, 21–22, 37,

64–65, 67–71

mismatch repair

16, 21–22, 37, 41, 64–65, 67–71

NCCN Member Institutions

89

NCCN Panel Members

88

polypectomy

12–13, 44, 53

polyp

12–13, 15–17, 24, 43–44, 47, 50, 53, 62

radiation therapy

27–30, 39, 41, 46, 48, 52–53,

57–58

RAS

16, 20, 67–71

shared decision–making

73, 79

supportive care

33, 67–71

survivorship

50, 60

targeted therapy

34–37, 41, 60, 64–65, 68, 70